A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with antineoplastic activity.
G-protein coupled receptor family C group 5 member D is primarily expressed in plasma cells and hard keratinozed tissues, with low expression in normal human tissues.
GPRC5D expression is enriched in malignant plasma cells and is associated with markers of high risk myeloma.
Talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.
Talquetamab Is a bispecific IgG4 anybody with a proline, alanine, alanine scaffold designed to minimize Fc receptor binding, binds to GPRC5D and CD3 to induce killing of GPRC5D expressing myeloma cells by means of a T cell recruitment and activation
Approved for a relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD 38 monoclonal antibody.
Side effects: cytokine release syndrome, skin related events, dysguesia, musculoskeletal, pain, skin disorder, rash, fatigue, decreased weight, dry mouth, pyrexia, xerosis, dysphagia, decreased upper respiratory tract, infection, and diarrhea.
Has a substantial response among patients with heavily pre-treated relapse to refractory multiple myeloma with response rate 64 to 70%, with a median duration response of 10.2 months and 7.8 months, respectively based on dose, schedule.
Approved on the results of the monumental-TAL-1 study:overall response rate was 73% in the median duration of response was 9.5 months.
There is a boxed warning label for life-threatening or fatal CRS, and neurological toxicity, including ICANS.
It is available only through REMS..